Benitec Ltd is a biotechnology company listed on the Australian Stock Exchange (ASX: BLT). Founded in 1997 to commercialise research from Queensland's Department of Primary Industries (DPI), Benitec is one of the pioneers of RNA interference (RNAi) technology, which can be used to precisely destroy RNA viruses and silence the expression of defective genes. Benitec's ongoing goal is to generate value through the commercialisation of ddRNAi in the area of human therapeutics.
The vision is for Benitec to be an internationally competitive company dedicated to the development of treatments for serious human diseases including infectious diseases, neurological disorders, cancer and autoimmune diseases, through leadership in RNAi technologies and strategic partnerships with leading biopharmaceutical companies and research organisations globally.
Non Renounceable Rights Issue
Click here to download a copy of the Prospectus for the Non Renounceable Rights Issue dated 1 April 2009.
If you have any queries regarding the rights issue, please contact the Company:
Chief Executive Officer Sue MacLeman at:
email: smacleman@benitec.com
tel: +61 (0)437 211 200
Company Secretary/CFO John Rawling at:
email: jrawling@benitec.com
tel: +61 (0)417 524 236
